137898-19-2

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 134-96-3 syringic aldehyde 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 121-33-5 vanillin 

Downstream Products

• 1011-27-4 3,5-dimethoxy-4-methylbenzaldehyde 
• 1055351-98-8 3',5'-dichloro-2,6-dimethoxybiphenyl-4-carbaldehyde 
• 1253733-46-8 3-(4-formyl-2,6-dimethoxyphenyl)acrylic acid methyl ester 
• 1351593-71-9 3,5-dimethoxy-4-(pyrrolidin-1-yl)benzaldehyde 
• 131157-32-9 4-Anilino-3,5-dimethoxybenzaldehyde 
• 1351593-17-3 4-(benzylamino)-3,5-dimethoxybenzaldehyde 
• 1253733-51-5 4-(3-hydroxy-propyl)-3,5-dimethoxybenzaldehyde 
• 1253733-50-4 3-(4-hydroxymethyl-2,6-dimethoxyphenyl)propan-1-ol 
• 1253733-49-1 3-(4-hydroxymethyl-2,6-dimethoxyphenyl)propionic acid 
• 1253733-48-0 3-(4-formyl-2,6-dimethoxyphenyl)propionic acid 
• 1253733-47-9 3-(4-formyl-2,6-dimethoxyphenyl)acrylic acid 
• 7311-34-4 3,5-dimethoxybenzaldehdye 
• 1351593-72-0 4-(3,5-dimethoxy-4-(pyrrolidin-1-yl)benzyl)-7-ethoxyisoquinolin-8-ol 
• 1351593-21-9 4-((2,6-dimethoxy-[1,1'-biphenyl]-4-yl)methyl)-7-ethoxyisoquinolin-8-ol hydrochloride 

Relevant academic research and scientific papers

Synthesis and biological evaluation of (3′,5′-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone selective CB2 inverse agonist

Cannabinoid receptor 2 (CB2) selective agonists and inverse agonists possess significant potential as therapeutic agents for regulating inflammation and immune function. Although CB2 agonists have received the greatest attention, it is emerging that inverse agonists also manifest anti-inflammatory activity. In process of designing new cannabinoid ligands we discovered that the 2,6-dihydroxy-biphenyl-aryl methanone scaffold imparts inverse agonist activity at CB2 receptor without functional activity at CB1. To further explore the scaffold we synthesized a series of (3′,5′-dichloro-2,6-dihydroxy-biphenyl-4-yl)-aryl/alkyl-methanone analogs and evaluated the CB1 and CB2 affinity, potency, and efficacy. The studies reveal that an aromatic C ring is required for inverse agonist activity and that substitution at the 4 position is optimum. The resorcinol moiety is required for optimum CB2 inverse agonist activity and selectivity. Antagonist studies against CP 55,940 demonstrate that the compounds 41 and 45 are noncompetitive antagonists at CB2.

Selective deoxygenation of hydroxybenzaldehydes

A method for selective deoxygenation of hydroxybenzaldehydes including, condensing syringaldehyde (3,5-dimethoxy-4-hydroxybenzaldehyde) and a functionalized phenylacetic acid with at least one first base and at least one anhydride to produce an arylcinnamic acid, decarboxylating of said arylcinnamic acid with at least one decarboxylation catalyst at temperatures ranging from about 30° C. to 200° C. or thermally at temperatures ranging from about 100° C. to 350° C. to produce a first stilbene, hydrodeoxygenating the stilbene by conversion to a sulfonate in the presence of at least one second base in water or at least one organic solvent to yield a sulfonate reducing the sulfonate(s) with a reductive elimination catalyst to produce a second stilbene, and reacting the second stilbene with a hydrolyzing agent to generate a polyphenol.

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

SUBSTITUTED ISOQUINOLINES AND THEIR USE AS TUBULIN POLYMERIZATION INHIBITORS

The present invention relates generally to substituted isoquinolines and their use as tubulin polymerization inhibitors. In particular, the invention relates to substituted isoquinolines which possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds

NOVEL ANTI-INFLAMMATORY AGENTS

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor

Two novel triaryl ligands 2 and 5 with potent in vitro binding affinities for the cannabinoid subtype-2 (CB2) receptor were labeled with a positron-emitting radioactive nuclide 11C. Radioligands [11C]2, [11C]5, and their analogs [11C]3 and [11C]4 were synthesized by O-[11C]methylation of their corresponding phenol precursors with [11C]CH3I. [11C]2-5 had relatively high uptakes (>1.2% injected dose/g tissue) in mouse brains.

Syntheses of naturally occurring cytotoxic [7.7]paracyclophanes, (-)-cylindrocyclophane A and its enantiomer, and implications for biological activity

The total syntheses of (-)-cylindrocyclophane A (1), a naturally occurring, cytotoxic [7.7]paracyclophane, and its enantiomer have been achieved in an enantiodivergent manner starting from a chiral propargyl alcohol building block using Smith's cross metathesis/ring-closing metathesis protocol as the key step. The biological evaluation of both enantiomers of cylindrocyclophane A (1 and ent-1) and its analogues indicated that the chirality of 1 is irrelevant to its cytotoxicity, which is attributed to the resorcinol motifs embedded in the robust [7.7]paracyclophane framework.

Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands

A novel series of cannabinoid ligands with a structurally unique tri-aryl core has been designed, synthesized and assayed. Receptor binding assays show that these compounds possess CB2 receptor sub-type selectivity with binding affinities ranging from 1.07 (±0.05) for 7 to 4.77 (±0.57) nM for 6. The selectivity of the compounds was enhanced 9-600-fold for the CB2 receptor over the CB1 receptor. The results of our present study identify a novel, highly selective cannabinoid scaffold with a non-classical core.

Tri-aryl/heteroaromatic cannabinoids and use thereof

Cannabinoid derivatives according to formula (I) are disclosed wherein, X, Y, R1, R2, and W can have the definitions provided herein. Without limitation, use of such compounds, their salts or pro-drug, or compositions containing the compounds, salts, or pro-drug, to modify the activity of CB1 and CB2 receptors and treat conditions mediated by these receptors.